To view this email as a web page, click here

Today's Rundown

Featured Story

Bischofberger's Kronos buys SYK inhibitors from Gilead

Ex-Gilead CSO Norbert Bischofberger has struck a deal with his former employer. The agreement will see Bischofberger’s Kronos Bio buy Gilead’s portfolio of spleen tyrosine kinase inhibitors and vault into clinical development.

read more

Top Stories

Relay passes the baton from private to public biotech, making $400M in the process

Relay Therapeutics has pulled off a major upsized IPO worth $400 million to propel a pipeline of treatments aiming at previously undruggable targets.

read more

COVID-19 close-up: Nocion CEO Batycky on controlling cough to control spread

Suppressing cough in COVID-19 patients not only addresses a symptom that can be “traumatic and debilitating,” but it can tamp down on the spread of the disease from patients to hospital staff, family or housemates. Nocion Therapeutics scored expedited approval for the phase 1 study of its cough treatment.

read more

Sponsored: Kupffer Cells in Complex In Vitro Cultures: An Important Tool For Drug Discovery

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

read more

Mallinckrodt's kidney failure med squeaks by FDA panel in 8-7 vote

An FDA panel has narrowly backed the approval of Mallinckrodt’s terlipressin for a type of kidney failure. The 8-7 vote comes after FDA staffers flagged multiple concerns for the drug, including whether meeting the surrogate endpoint in its phase 3 study actually translated to patients living longer or faring better.

read more

Adagio debuts with $50M to fight COVID-19—and the next pandemic

Coronaviruses have jumped from animals to humans before—and they’ll do it again. That’s why Adagio Therapeutics is working on antibodies that can fight multiple members of the virus family, including SARS-CoV-2, the culprit behind the current pandemic. The startup snagged $50 million to push its lead candidates into the clinic.

read more

Imvax raises $112M to advance brain cancer cell therapy

Imvax has raised $112 million to take its autologous tumor cell vaccine into a phase 2 glioblastoma multiforme trial. The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD Holding and Ziff Capital Partners to commit more cash.

read more

Glympse Bio secures $46M to boost its injectable diagnostics for NASH, cancer and more

Glympse Bio, developers of an injectable chemical biomarker platform for diagnosing the body’s hidden diseases, has raised $46.7 million in new funding for its efforts.

read more

Johnson & Johnson to start human testing of COVID-19 vaccine next week: exec

Several biopharma players are racing to deliver COVID-19 vaccines, and now Johnson & Johnson is revving up its plans for late-stage trials earlier than originally expected—and it's aiming far above the FDA's 50% efficacy bar for approval, executives said. If its candidate succeeds in the clinic, J&J plans to be ready to launch in early 2021.

read more

Resources

Whitepaper: High-Loaded Dosage Forms: Novel Platform Expands Spray-Dried Dispersion Utility

A novel spray-dried dispersion platform has been developed to faciliate high drug load applications

Whitepaper: How to Harness the eISF to Accelerate Clinical Operations

Complimentary Download: How to connect to study sites remotely via the Electronic Investigator Site File (eISF) to streamline clinical operations. Insights from the largest eISF network in the world.

Whitepaper: Learn How to Navigate Pediatric Clinical Trials Under the New RACE Act

Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need.

On-Demand Webinar: Fuel gene therapy development and production with modern AAV workflows

On-demand video: fuel gene therapy development and production with modern AAV workflows.

With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before.

eBook: Cambrex eBook - Small molecules: 2020 vision

The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet.

White Paper: Patient Switching Behaviors Impact on Adherence and Engagement: A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes

How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.”

Whitepaper: You've Decided on a Multiparticulate Dosage Form. Now What?

Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project.

Webinar: Blockchain Innovations that Connect & Protect Merck's Supply Chain

Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain.

eBook: SUPERCHARGE INNOVATION: UNLEASH THE FULL FORCE OF LIFE SCIENCES

Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense.

Whitepaper: 4 Ways to Keep Pace with Big Pharma, Even On a Start-Up Budget

Learn four ways to squeeze more value from your limited R&D resources.

eBook: Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies

Download this eBook and Learn the Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies

Case Study: Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

Fact Sheet: Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events